20:16 , Mar 24, 2017 |  BC Week In Review  |  Company News

Critical Path biomarker consortium

The Critical Path Institute launched a consortium that will aim to qualify biomarkers for Type I diabetes with FDA and EMA. The Leona M. and Harry B. Helmsley Charitable Trust, the Janssen Research & Development...
21:59 , Mar 21, 2017 |  BC Extra  |  Politics & Policy

C-PATH consortium seeks to qualify diabetes biomarkers

The Critical Path Institute (Tucson, Ariz.) launched a consortium that will aim to qualify biomarkers for Type I diabetes with FDA and EMA. The Leona M. and Harry B. Helmsley Charitable Trust , the Janssen...
07:00 , Oct 6, 2014 |  BioCentury  |  Emerging Company Profile

Nirmidas: Improving NIR-sightedness

Nirmidas Biotech Inc. 's pGOLD platform can amplify the signal output of near-infrared fluorescent dyes over a hundredfold, which improves their sensitivity for low-concentration analytes in ELISA or other assays that rely on fluorescent readouts....
07:00 , Apr 23, 2009 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Caenorhabditis elegans model of neurosecretion A C. elegans model of neurosecretion could be useful for guiding the development of strategies to...